Centre allows commercial launch of first CRISPR Covid-19 test | All you need to know
Click here to read full article from source
India, Sept. 19 -- The Drug Controller General of India (DGCI) on Saturday approved country's first Clustered Regularly Interspaced Short Palindromic (CRISPR) Covid-19 test for commercial launch. This is developed by Tata and powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA (an acronym for FNCAS9 Editor-Limited Uniform Detection Assay).
"The approval for the Tata CRISPR test for COVID-19 will give a boost to the country's efforts in fighting the global pandemic. The commercialization of the Tata CRISPR test reflects the tremendous R&D talent in the country, which can collaborate to transform India's contributions to the global healthcare and scientific research world," Girish Krishnamurthy, CEO, TATA Medical an...
To read the full article or to get the complete feed from this publication, please Contact Us